NCT05404763进行中（未招募）不适用
Evolution of Physical Activity in Severe Asthmatic Patients Treated With Mepolizumab
University Hospital, Lille2 个研究点 分布在 1 个国家目标入组 62 人开始时间: 2023年2月2日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 62
- 试验地点
- 2
- 主要终点
- Number of daily steps
研究概览
简要总结
Severe asthma is a debilitating condition associated with frequent symptoms, life-threatening exacerbations and corticosteroid side-effects. Exercise limitation due to exercise-induced bronchoconstriction, dynamic lung hyperinflation and comorbidity may be a strong determinant of the disease burden. Mepolizumab is a monoclonal anti-interleukin-5 (IL-5) antibody that reduces the rate of severe exacerbations, asthma symptoms and oral glucocorticoid requirement, and improves quality of life and work productivity in severe eosinophilic asthma. However, its impact on physical activity and exercise tolerance is unknown. We hypothesize that a 6-month treatment with mepolizumab is associated with an improvement in daily life physical activity and exercise tolerance in relation with enhanced ventilatory mechanics.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age between 18 and 75 years at the time of inclusion
- •Asthma diagnosed for at least one year including a history of
- •FEV1 and/or FVC reversibility of more than 12% and than 200 ml documented in the patient's record
- •OR FEV1 variability of more than 20% between two visits
- •OR positive methacholine test
- •Severe uncontrolled asthma monitored for at least six months in the investigation center with at least two assessments:
- •high-dose of inhaled corticosteroids (ICS >1,000 μg/day of beclometasone equivalent) in combination with another controller at a stable dosage for at least three months
- •ACQ-5 score >1.5 and/or more than two severe exacerbations (i.e exacerbation requiring ≥ 3 days of systemic corticosteroids, hospitalization or admission at the emergency department) in the past year
- •Blood eosinohils ≥300/mm3 within the 12 past months
- •Decision to introduce mepolizumab according to regulatory approval
- •Patient agreement to receive Mepolizumab
- •Body mass index (BMI) within the range [18.5 - 35] kg/m
- •Able to give signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
排除标准
- •Body Mass Index <18.5 or >35 kg/m2
- •Active smoker or active smoking during the last 6 months or cumulative > 10 pack-years
- •All conditions responsible for physical disability (neurological, orthopedic, psychiatric, non-exhaustive list) or other condition limiting exercise in the investigator's opinion
- •Any chronic respiratory or cardiac pathology which may interfere with the assessment of asthma according to the investigator's opinion
- •Prior treatment with mepolizumab or benralizumab
- •Bronchial thermoplasty during the past 12 months
- •Contraindication to mepolizumab
- •Non-coverage by the social security insurance
- •Pregnant, breastfeeding, or lactating women
- •Patient unable to receive information
- •Refusal to sign the consent form
- •Unwillingness or inability to follow the study procedures, in the opinion of the investigator
- •Person deprived of the liberty Person benefiting from a system of legal protection (guardianship…)
结局指标
主要结局
Number of daily steps
时间窗: after 6 months of treatment with mepolizumab
次要结局
- Endurance time during a sub-maximal exercise (80% of maximum load)(Baseline, at 3 months and at 6 months)
- Baseline Dyspnea Index (BDI)(Baseline, at 3 months and at 6 months)
- Multidimensional Dyspnea Profile (MDP) scores(Baseline, at 3 months and at 6 months)
- ACQ-5 score(Baseline, at 3 months and at 6 months)
- Respiratory capacity by Spirometry(Baseline, at 3 months and at 6 months)
- Respiratory capacity by plethysmography(Baseline, at 3 months and at 6 months)
- Ventilatory function by Spirometry(Baseline, at 3 months and at 6 months)
- Frequency of serious and non-serious side effects(Baseline, at 3 months and at 6 months)
- Time with moderate physical activity (between 3 and 6 METs) and intense activity (>6 METs)(Baseline, at 3 months and at 6 months)
- Percentage of time spent with moderate physical activity (between 3 and 6 METs) and intense activity (>6 METs)(Baseline, at 3 months and at 6 months)
- Ricci and Gagnon questionnaire score •(Baseline, at 3 months and at 6 months)
- Transition Dyspnea Index (TDI) scores(Baseline, at 3 months and at 6 months)
- Hospital Anxiety and Depression scores (HADS)(Baseline, at 3 months and at 6 months)
- AQLQ score(Baseline, at 3 months and at 6 months)
- Forced inspiratory by Spirometry(Baseline, at 3 months and at 6 months)
- Forced oscillation by impulse oscillometry (the Tremoflo ® oscillometry system)(Baseline, at 3 months and at 6 months)
- The modified Medical Research Council (mMRC) scale(Baseline, at 3 months and at 6 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Evaluation of Physical Activity in Asthmatic SubjectsPhysical ActivityAsthmaNCT05486689Istituti Clinici Scientifici Maugeri SpA17
已完成
不适用
Behavioral Intervention to Increase Physical Activity in Patients with Asthma: Identifying RespondersAsthmaNCT05159076University of Sao Paulo General Hospital100
已完成
不适用
Investigation of Physical Activity Level, Cardiorespiratory Fitness and Quality of Life in Patients With AsthmaPhysical ActivityAsthmaNCT03509311Gazi University72
已完成
3 期
Impact of Aerobic Exercise on Asthma MorbidityAsthmaNCT00953342Hopital du Sacre-Coeur de Montreal66
已完成
不适用
Longitudinal Observational Study of Severe AsthmaAsthmaNCT01780142National Heart, Lung, and Blood Institute (NHLBI)171